1. Signaling Pathways
  2. MAPK/ERK Pathway
    Stem Cell/Wnt
  3. ERK
  4. ERK Inhibitors

ERK Inhibitors

ERK

ERK1

ERK2

ERK5

ERK8

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

ERK Degraders, Inhibitors & Activators
Product Name ERK ERK1 ERK2 ERK5 ERK8 Purity
PD98059  
ERK1
ERK2
    99.96%
Yoda 1  
ERK1
ERK2
    99.98%
SCH772984  
ERK1, IC50: 4 nM
ERK2, IC50: 1 nM
    99.27%
TBHQ
ERK
        99.89%
Tauroursodeoxycholate
ERK
        99.91%
Ulixertinib    
ERK2, IC50: 0.3 nM (at KM ATP (60 μM))
    99.95%
Honokiol  
ERK1
ERK2
    99.90%
β-Glycerophosphate disodium salt pentahydrate  
ERK1
ERK2
    ≥98.0%
Astragaloside IV  
ERK1
ERK2
    ≥98.0%
Piperlongumine  
ERK1
ERK2
    99.87%
Tauroursodeoxycholate sodium
ERK
        98.88%
Temuterkib  
ERK1, IC50: 5 nM
ERK2, IC50: 5 nM
    99.94%
Ravoxertinib  
ERK1, IC50: 6.1 nM
ERK2, IC50: 3.1 nM
    99.75%
C16-PAF
ERK
        99.48%
Lidocaine
ERK
        99.96%
Fucoxanthin    
ERK2
    99.47%
FR 180204  
ERK1, Ki: 0.31 μM
ERK1, IC50: 0.51 μM
ERK2, Ki: 0.14 μM
ERK2, IC50: 0.33 μM
    99.64%
β-Glycerophosphate disodium salt hydrate  
ERK1
ERK2
    ≥98.0%
BIX02189      
ERK5, IC50: 59 nM
  99.99%
6-OAU
ERK
        99.91%
trans-Zeatin
ERK
        99.83%
XMD8-92      
BMK1, Kd: 80 nM
  99.67%
ASN007  
ERK1
ERK2
    99.70%
MK-8353  
ERK1, IC50: 23 nM
ERK2, IC50: 8.8 nM
    99.30%
Lysophosphatidylcholines  
ERK1
ERK2
    ≥99.0%
Pachymic acid
ERK
        ≥99.0%
Lidocaine hydrochloride
ERK
        99.96%
VX-11e    
ERK2, Ki: 2 nM
    99.17%
KO-947  
ERK1
ERK2
    99.61%
LM22B-10
ERK
        99.92%
AG126    
ERK2
    ≥98.0%
Tizaterkib    
ERK2, IC50: 0.6 nM
    99.31%
AX-15836      
ERK5, IC50: 8 nM
  99.68%
Peiminine  
ERK1
ERK2
    99.94%
DEL-22379    
ERK2, IC50: 0.5 μM
    99.76%
CHPG sodium salt
ERK
        99.25%
ASTX029  
ERK1
ERK2
    99.82%
Pluripotin  
ERK1, Kd: 98 nM
      98.86%
Cafestol
ERK
        99.91%
Rineterkib  
ERK1
ERK2
    99.83%
Broussonin E
ERK
        98.18%
Ravoxertinib hydrochloride  
ERK1, IC50: 6.1 nM
ERK2, IC50: 3.1 nM
    99.93%
Mogrol  
ERK1
ERK2
    99.25%
CC-90003  
ERK1
ERK2
    99.71%
MAP855
ERK, EC50: 5 nM
        99.38%
BIX02188      
ERK5, IC50: 810 nM
  99.85%
XMD17-109      
ERK5, IC50: 162 nM
  99.20%
JWG-071      
ERK5, IC50: 88 nM
  99.15%
ERK1/2 inhibitor 1    
ERK2, IC50: 3.0 nM
    99.79%
Magnolin  
ERK1, IC50: 87 nM
ERK2, IC50: 16.5 nM
    99.98%
ERK5-IN-2      
ERK5, IC50: 0.82 μM
ERK5 MEF2D, IC50: 3 μM
  98.97%
Cearoin
ERK
        ≥98.0%
Peramivir  
ERK1
ERK2
    98.19%
4-Methylbenzylidene camphor  
ERK1
ERK2
    99.87%
Corynoxeine  
ERK1
ERK2
    99.93%
ASN007 benzenesulfonate  
ERK1
ERK2
    98.06%
H-Ile-Lys-Val-Ala-Val-OH  
ERK1
ERK2
    99.12%
CK2/ERK8-IN-1        
ERK8, IC50: 0.5 μM
≥99.0%
ERK5-IN-1      
ERK5, IC50: 87 nM
  99.33%
CHPG
ERK
        ≥99.0%
2,5-Dihydroxyacetophenone  
ERK1
ERK2
    99.75%
β-Neo-Endorphin  
ERK1
ERK2
    98.22%
BAY885      
ERK5, IC50: 35 nM
  99.27%
Deltonin  
ERK1
ERK2
    99.94%
Lidocaine (Standard)
ERK
        99.85%
Sanggenon C
ERK
        98.50%
Loureirin B
ERK
        99.16%
Longdaysin    
ERK2, IC50: 52 μM
    99.87%
Bohemine    
ERK2, IC50: 52 μM
    98.93%
ERK-IN-4    
ERK2, Kd: 5 μM
    99.61%
I-287  
ERK1
ERK2
   
Myristicin
ERK
        99.89%
Anti-inflammatory agent 35
ERK
        99.77%
Omtriptolide
ERK
       
EVT801
ERK, IC50: 13 nM
       
Methylnissolin  
ERK1
ERK2
    99.86%
Hypothemycin  
ERK1, Ki: 8.4 μM
ERK2, Ki: 2.4 μM
    ≥98.0%
ML192  
ERK1
ERK2
   
Methylthiouracil  
ERK1
ERK2
    ≥98.0%
Syk-IN-6  
ERK1
ERK2
   
AT-533  
ERK1
ERK2
    98.86%
HIOC
ERK
       
[Tyr8] Bradykinin  
ERK1
ERK2
    99.61%
Enniatin B1
ERK
       
ERK5-IN-5      
ERK5
  99.05%
ERK1/2 inhibitor 9  
ERK1
ERK2
   
Isoprocurcumenol
ERK
       
ERK2 IN-1    
ERK2, IC50: 7 nM
   
ERK-IN-2    
ERK2, IC50: 1.8 nM
   
ERK5-IN-3      
ERK5, IC50: 6 ± 1 nM
 
PT-262
ERK
        99.21%
Aloisine A  
ERK1, IC50: 18 μM
ERK2, IC50: 22 μM
   
ZINC12409120
ERK, IC50: 5 μM
       
ERK-IN-7  
ERK1, IC50: 5 nM
ERK2, IC50: 7 nM
   
ERK-IN-2 free base    
ERK2, IC50: 1.8 nM
   
DCZ19931  
ERK1
ERK2
   
MHJ-627      
ERK5
 
PPM-3      
ERK5, IC50: 62.4 ± 18. nM
 
Enniatin B
ERK
        99.10%
ERK2-IN-4    
ERK2, Ki: 0.006 μM
   
ERK2 allosteric-IN-1    
ERK2, IC50: 11 μM
   
CKLF1-C27 TFA  
ERK1
ERK2
   
Enniatin A1
ERK
       
Anti-inflammatory agent 31  
ERK1
ERK2
   
SHR2415  
ERK1, IC50: 2.8 nM
ERK2, IC50: 5.9 nM
    98.63%
ERK1/2 inhibitor 10  
ERK1, IC50: 0.11 nM
ERK2, IC50: 0.8 nM
   
Myristoyl-MEK1 Derived Peptide Inhibitor 1
ERK, IC50: 13 μM (The in vivo inhibitory potency is determined in both PMA-treated NIH 3T3 cells and NGF-stimulated PC12 cells.)
 
ERK2, IC50: 10 μM (The in vitro inhibitory potency of the peptides is measured based on their ability to inhibit MEK1-mediated phosphorylation of ERK2. )
   
CXJ-2
ERK
       
MK2-IN-5  
ERK1
ERK2
   
Cudraflavone B
ERK
       
Lidocaine hydrochloride hydrate
ERK
       
ERK5-IN-4      
ERK5
 
CKLF1-C27  
ERK1
ERK2
    98.50%
Sugiol  
ERK1
ERK2
   
ERK5-IN-6
ERK
       
Phenylhydroquinone  
ERK1
ERK2
   
Tizaterkib (hexanedioic acid)    
ERK2, IC50: 0.6 nM